ArticleInvestigative ophthalmology & visual science2024
Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.
Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Pooled it
- [Pioneering trials in ophthalmology-From clinical trials to guideline treatment].Die Ophthalmologie · 2026Article
- From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME.Journal of clinical medicine · 2026Review
- Dynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab.Journal of clinical medicine · 2026Article
- Real-world comparative effectiveness of faricimab versus aflibercept 2 mg in treatment-naïve exudative neovascular AMD patients treated with a treat-and-extend regimen.Eye (London, England) · 2026Article
- Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore.Ophthalmology and therapy · 2026Article
- First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria.Journal of clinical medicine · 2026Article
- Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.Ophthalmology science · 2026Article
- Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study.Journal of clinical medicine · 2026Article
- Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study.BMC ophthalmology · 2026Observational
- First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.BMJ open ophthalmology · 2026Article
- Observational
- Aqueous humor cytokine levels in retinal vein occlusion patients with suboptimal response to anti-VEGF therapy and the correlation with OCT imaging biomarkers.European journal of medical research · 2025Article
- Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?Ophthalmology and therapy · 2025Article
- Efficacy and Safety of Faricimab in Diabetic Macular Edema: Real-World Outcomes in Treatment-Naïve and Previously Treated Eyes.Journal of clinical medicine · 2025Article
- Author Response: Retina Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.Investigative ophthalmology & visual science · 2025Article
- Comments on "Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema".Investigative ophthalmology & visual science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the anatomic and functional outcomes in eyes with diabetic macular edema (DME) switched from intravitreal aflibercept to faricimab in a real-world setting. Methods: Retrospective, interventional consecutive case series. Patients with DME were switched from aflibercept to faricimab and categorized based on central subfield thickness (CST) 4 weeks after last aflibercept injection into responding DME (rDME, CST reduction >20% or CST ≤ 250 µm) and nonresponding DME (nrDME, CST unchanged or increased). Patients received a loading dose of two monthly faricimab injections followed by a treat-and-extend regimen. Differences in response between rDME and nrDME were analyzed based on injection interval, change in CST, and visual acuity (VA) 12 weeks postswitch. Results: Fifty-two eyes of 40 patients met inclusion criteria (rDME: n = 26, nrDME: n = 26). Baseline and week 12: VA (logMAR) rDME 0.29 ± 0.23 and 0.22 ± 0.28, nrDME 0.42 ± 0.32 and 0.36 ± 0.29; CST (µm) rDME 370 ± 99 and 288 ± 80, nrDME 384 ± 85 and 380 ± 129. After 12 weeks, 54% rDME and 25% nrDME eyes showed a CST decrease of >20% or CST ≤ 250 µm. Forty-six percent rDME and 50% nrDME eyes had a ±20% CST change, 25% of nrDME eyes had a >20% CST increase, and 73% of rDME eyes and 47% of nrDME eyes reached an extended interval of 8 weeks or longer after 12 weeks. Conclusions: Most DME eyes previously responding or not responding to aflibercept experienced a reduction or stabilization of DME after 12 weeks of faricimab treatment. rDME showed a better anatomic response, and treatment intervals could be extended earlier and longer than nrDME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.